Solana Company (HSDT)

$4 neurological tongue action and now a Solana Treasury company 

YES. Isn't that blatantly obvious at this junction?

Crappier News! 1:50 RS effective June 30th! BOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOO

News!

Helius Medical Unveils Revelation Neuro to Pioneer AI-Powered Neurorehabilitation https://share.google/4sUVBZYMq3swJz8lq

Hi Jazz....Im just playing that drop on the 16th. Just keeping a close eye at this point.

HI, I got in with a small 5K and that was purely because of the high volume. Any thoughts you can share for this stock? short or long term?

Hey man...I am for 20k shares. 15k shares bought in the mid to low .30's. The other 5k shares around mid .60's.

Hey, bro, are you still in this? Huge volume pouring in. Price in the .40's

This is horrible! And even with today's good news! Wonder if its holder in the Caymen Islands that's screwing everyone by naked shorting.

Wow...wtf happen to this thing

Haha....appreciate that subslover!

Good luck! I'm rooting for you!😁

Reloaded....let's see what she's got...

IMHO, it's a travesty. It's a travesty of a mockery of a sham of a mockery of two mockeries of a sham

Dodged a bullet there at the end of the day. Unloaded all but 1000 shares. 15 minutes later, the bottom dropped out. Trying to get back in hahaha

AHHHH....no worries. I misinterpreted your post.

Excuse my bad english ... i mean this stock hit bottom due to stock price offerings..

What do you mean "super low share price offering"? The offering, which is relatively small ($9.1M), was for $3.27/share. I know it has warrants mixed in there but those have an initial exercise price of $7.3575.

Lastly, given the small float, this offering shouldn't be too impactful as it was set to close already (June 6th).

no buy remorse few days ago ... Wish to bet this ... congrats to all of you that bought and hold after hit super low share price offering take away lots of shares ...

Helius Medical Technologies, Inc. Announces Authorized Claim for Payment by Major Healthcare Payer for its Portable Neuromodulation Stimulator (PoNS®) Device
-Aetna authorizes claim for PoNS Device at out-of-network negotiated price of $18,350, becoming the third payer to join Anthem and United in providing PoNS reimbursement-

-Out of Network reimbursement is only the first step towards expanding third-party paid access to PoNS-

NEWTOWN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced an authorized claim for payment for the PoNS Device from a third major healthcare provider, Aetna Healthcare.

“The recent reimbursement approvals from two major commercial healthcare payers, with a third underway, mark significant milestones for Helius and the MS community,” said Dane Andreeff, Helius’ President and Chief Executive Officer. “We are actively pursuing broader in-network coverage for PoNS at list price from major commercial payers, while continuing to negotiate reimbursement on a case-by-case basis. We expect to continue our efforts in expanding patient access and ensuring consistent reimbursement as we work to align commercial payments with the rates currently offered by the VA/DoD at $26,228. At the same time, we remain firmly committed to supporting individuals with MS who rely on Medicare for PoNS treatment and believe this, along with other 3rd party payer reimbursement decisions will benefit our continued efforts to secure fair and adequate reimbursement by CMS for the PoNS system.”

The out-of-network price, which typically is 30 to 40% below in-network contracted payment rates of $18,350, was negotiated and accepted by Aetna Healthcare to fulfill the prescription of the PoNS Device for an individual with multiple sclerosis. Depending on the individual’s deductible and out-of-pocket costs, this claim may not result in an immediate PoNS Device sale.

HSDT................................................................p/m

Was a lucrative day yesterday from those levels.

I threw a couple grand at it this AM @ .73. I don't know what happened to drop the stock 78%.

Good move off .70 this morning...

Looks good .70

$HSDT Helius Medical Technologies, Inc. Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $3.7 Million Gross Proceeds Priced At-the-Market— THE FINAL COUNTDOWN (@THIS_TIME_X) January 22, 2025

Never mind - my streaming wasn't working right. Sorry if I alarmed anyone.

BB

Did HSDT get suspended?

Big Benny

Helius Medical Technologies, Inc. Announces Strong Enrollment of its Stroke Pivotal Study Exceeding Initial Target
--128 enrolled participants, as of December 31, 2024, exceeds initial target of 90 participants--

--150 maximum participant enrollment projected by end of January--

--The stroke registrational program is intended to demonstrate the safety and effectiveness of the novel Portable Neuromodulation Stimulator (PoNS®) for improving balance and gait deficits in stroke survivors--

--On track for FDA submission for stroke authorization in the second quarter of 2025--

NEWTOWN, Pa., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced it has completed and far exceeded the initial target enrollment for its stroke registrational program. With 128 participants randomized to-date the program is on track to reach the maximum enrollment target of 150 participants by the end of January 2025.

“Gait and balance deficits are the most frequently occurring disability in stroke patients and represent the largest market opportunity for PoNS Therapy®,” said Dane Andreeff, Helius Medical President and Chief Executive Officer. “We are excited for the opportunity to make PoNS available to the over 7 million patients in the U.S. living with disability from stroke as we remain on target to achieve FDA authorization for stroke in 2025.”

In 2021, the U.S. Food and Drug Administration granted Breakthrough Designation for PoNS in stroke. Helius has designed and implemented the stroke registrational program to establish the effects of cranial-nerve non-invasive neuromodulation (“CN-NINM”), delivered using PoNS Therapy, on gait and balance in chronic stroke survivors to support an FDA submission to expand the PoNS device indication to this patient population. The registrational studies also aim at establishing PoNS efficacy on decreasing risk of falling and maintaining the therapeutic effect post-treatment.

“Completing enrollment of our registrational program’s studies is a significant step toward providing stroke patients with a new therapeutic tool to improve their mobility. We have shown PoNS is effective in treating gait deficits for MS patients and we are excited to reinforce similar therapeutic benefits to address a dire medical need in this patient population,” said Antonella Favit-Van Pelt, M.D., Ph.D., Helius Chief Medical Officer. “Our ability to enroll this study in a timely manner highlights providers’ interest in PoNS Therapy and demonstrates patients’ demand for impactful rehabilitation therapies. With maximum target enrollment expected by the end of the month, we are tracking to our goal to submit for stroke authorization in the second quarter of 2025.”

In March 2023, the FDA endorsed the stroke registrational program which originally included two initial studies. The first was an investigator-initiated randomized placebo-controlled trial (MUSC-RCT) in approximately 60 subjects, led by Dr. Steven Kautz at the Medical University of South Carolina (MUSC) and Dr. Mark Bowden at Brooks Rehabilitation. The second study was a company-sponsored open-label study (HMI-OLS), in approximately 30 subjects. In May 2024, Helius added a third company-sponsored randomized placebo-controlled trial (HMI-RCT) across five sites in Canada and the U.S. All three studies shared the same design and endpoints, including primary outcomes on gait and balance improvement, as well as key secondary endpoints with Type 1 error of reduced risk of falling and maintenance of effect at 12 weeks post-treatment.

Enrollment of the stroke registrational studies started at MUSC for the MUSC-RCT in August 2023 and, at Brooks Rehabilitation, in August 2024. In June 2024, Helius started enrollment of the HMI-OLS at five U.S. Centers of Excellence for Neurorehabilitation including Shepherd Center, MGH-IHP, REHABOLOGYM, Brooks Rehabilitation and New England Neurological Center. Enrollment continued, with the HMI-RCT, in July 2024 at Neuro-Concept Rehabilitation Center, Neuphysio, Synaptic Health, Bergin Motion in Canada and REHABOLOGYM in the U.S.

“By December 31, 2024, we have reached our goal and exceeded our previously communicated target enrollment of 90 subjects, by randomizing 128 participants across the three registrational programs’ studies and we expect to reach our full enrollment of 150 participants in the next couple of weeks. Achieving and exceeding enrollment rate of approximately 5 participants per site per month in such a short timeframe, significantly outperforming the enrollment benchmark for stroke-related medical device studies, is a monumental achievement for Helius,” Dr. Favit-Van Pelt continued. “We are grateful to all our investigators for their extraordinary contribution and dedication to make PoNS Therapy available to stroke patients.”

About the PoNS Device and PoNS Therapy
The Portable Neuromodulation Stimulator (“PoNS”) is an innovative, non-implantable, orally applied therapy that delivers neurostimulation through a mouthpiece connected to a controller while it’s used, primarily at home, with physical rehabilitation exercise, to improve balance and gait. The PoNS device, which delivers mild electrical impulses to the tongue, is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (“MS”) and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.

PoNS has shown effectiveness in treating gait or balance and a significant reduction in the risk of falling in stroke patients in Canada, where it received authorization for sale in three indications: (i) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from stroke and is to be used in conjunction with physical therapy; (ii) for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used in conjunction with physical therapy; and (iii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy. PoNS is also authorized for sale in Australia for shor

HSDT: THAT would be FINE!!

LOL.... "Here’s Johnny ! " Tomorrow morning will be more upside! Let's go HSDT !

HSDT: See ME recently, below, deploying HSDT's disruptive, revolutionary, new "Portable Neuromodulation Stimulator System"!!! (It's guranteed to staff-off, "Early-Onset-Old-Timers-Disease", as well as help prevent HAIR LOSS, to boot!!!)

HSDT: The Old Fart Scores Again??!! (WHO says that?!)

so we buying or what? lol

same promoter just alerted it again

no news just alerted by a stock promoter, while running hot in the low float mania

SO WHAT'S THE NEWS HERE ???

hsdt................................https://stockcharts.com/h-sc/ui?s=hsdt&p=W&b=5&g=0&id=p86431144783

HSDT: CONGRATS!! (However, regarding your comment, "when the officer ran back and picked the child up
did the child say my phone?", on you "X" homepage --- you have to understand that such a PHONE for such a little GIRL represents her entire UNIVERSE of friends, pals, Homegirls, parents, relatives, fun sights, fun sounds, ad infinitum, to the core of her BEING, Bro!!! Even as an ATHEIST, I know that TRUTH!!! How about YOU??????? (HA-HA-HA!!!)

I agree with you🤩

HSDT: 3-times your money already --- not bad, Admiral T-F-C-D!!! (I know you HATE that!!)

$1.51 208% Starting to stall out might want to cash out 4m
Floater

Not bad 200% $1.40 still going some

$HSDT.80 trade idea @MoonMarket_ pic.twitter.com/f3A4L96Trm— THE FINAL COUNTDOWN (@THIS_TIME_X) December 20, 2024

HSDT new 52 week low

Helius Medical Technologies, Inc. Announces Reimbursement Payment Determination Updates from CMS for its Portable Neuromodulation Stimulator (PoNS®) Controller and Mouthpiece

IS THIS STOCK A SCAM OR WHAT??? I WANT THE TRUTH!!!

HSDT new 52 week low

HSDT new 52 week low

company received HCPCS codes and CMS reimbursement. They also sign up VA distributor.
Blue Cross is reimbursing